• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks

Dig Into Grand Canyon, Weatherford Shares Says Thornburg Value Manager

Shares of Grand Canyon Education (LOPE) have fallen over 18% so far in 2015, but they have still outperformed the rest of the beleaguered for-profit education sector.
By GREGG GREENBERG Oct 28, 2015 | 03:17 PM EDT
Stocks quotes in this article: TVAFX, LOPE, SGEN, WFT, FB

Shares of Grand Canyon Education (LOPE) have fallen over 18% so far in 2015, but they have still outperformed the rest of the beleaguered for-profit education sector. Connor Browne, portfolio manager of the Thornburg Value Fund (TVAFX), said Grand Canyon has the best chance of the bunch to dig itself out of its current hole. 'They operate a ground campus in Arizona, it’s a beautiful campus that you can look up on the Web site,' said Browne. 'Growing that ground campus where they are getting good outcomes for a student at a good price strengthens the online brand.' The Thornburg Value Fund is up 2.7% so far this year, according to fund-tracker Morningstar. The $925 million fund is outpacing 85% of its peers in Morningstar’s large blend category. Browne is also positive on shares of Seattle Genetics (SGEN), which are up over 31% year-to-date even after a wild ride in the market. He said the company’s antibody-based therapies for the treatment of cancer have tremendous upside, especially its lead product Adcetris, which he says is just scratching the surface. 'They have seven clinical programs, early stage clinical programs and another four headed into the clinic later this year,' said Browne. 'That’s a lot of shots on goal, if one of them hits it could double the market cap of the business.'

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

TAGS: Education | Investing | Video | Oil Equipment/Services | Oil | Biotechnology | Natural Gas | Healthcare | Technology | Opinion | Energy | Stocks | Earnings | Executive Interview

More from Education

I'm Going Public -- With My Favorite 'IPO' of the Year

Stephen Guilfoyle
Dec 31, 2021 12:30 PM EST

Roblox was a 'metaverse'-style company before the word was cool. Here's why I'm hot on this name.

Investors Are Getting Schooled by Chegg, So Let's Study the Charts

Bruce Kamich
Nov 2, 2021 12:52 PM EDT

We did our homework on this one in February and now we're learning a hard lesson about what's next.

Visit Grand Canyon to Book Nice Profits

Paul Price
Nov 16, 2020 7:00 AM EST

Grand Canyon Education is a great "left to right" stock with a low valuation.

Lessons of the 'Dividend Derby'

Chris Versace
Oct 12, 2020 11:30 AM EDT

Let's look at how increases to a quarterly dividend payment should be scrutinized by investors as we compare the moves in three companies.

This Dividend Stock's a Textbook Example of a Solid Investment

Bob Ciura
Sep 11, 2020 11:18 AM EDT

Publisher John Wiley & Sons is a small cap gem, yielding 4%.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login